Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Hariharan Subramanian, Anja von Heydebreck, Vijay Kasturi, Vikram K. Chand, James L. Gulley
Format: Artigo
Jezik:engleski
Izdano: 2018
Online pristup:https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

https://doi.org/10.1186/s40425-018-0424-9
https://jitc.bmj.com/content/jitc/6/1/111.full.pdf

Slični predmeti